<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04608344</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-417-5937</org_study_id>
    <nct_id>NCT04608344</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants</brief_title>
  <official_title>A Phase 1 Study to Evaluate OATP Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the effect of filgotinib on a mixed&#xD;
      organic anion transporting polypeptide/cytochrome P450 3A (OATP/CYP3A), OATP/ breast cancer&#xD;
      resistance protein (BCRP), and OATP substrates using phenotypic probes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 4, 2020</start_date>
  <completion_date type="Actual">January 13, 2021</completion_date>
  <primary_completion_date type="Actual">January 13, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Concentration Versus Time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of ATV, PRA, and ROS</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours post dose (Sequence AB: Days 1 and 12 up to 48 hours; Days 3 and 14 up to 72 hours. Sequence BA: Days 6 and 18 up to 48 hours; Days 8 and 20 up to 72 hours)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration Versus Time Curve Extrapolated to Infinite Time (AUCinf) of ATV, PRA, and ROS</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours post dose (Sequence AB: Days 1 and 12 up to 48 hours; Days 3 and 14 up to 72 hours. Sequence BA: Days 6 and 18 up to 48 hours; Days 8 and 20 up to 72 hours)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) for ATV, PRA, and ROS</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours post dose (Sequence AB: Days 1 and 12 up to 48 hours; Days 3 and 14 up to 72 hours. Sequence BA: Days 6 and 18 up to 48 hours; Days 8 and 20 up to 72 hours)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Treatment-Emergent Adverse Events</measure>
    <time_frame>Up to 26 days for sequence AB and up to 29 days for sequence BA</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Laboratory Abnormalities</measure>
    <time_frame>Up to 26 days for sequence AB and up to 29 days for sequence BA</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Sequence AB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin (ATV) 40 mg (Day 1); Washout period (Day 2); Pravastatin (PRA) 40 mg + Rosuvastatin (ROS) 10 mg (Day 3); Washout period (Days 4-6) in Treatment A Period 1; Filgotinib (FIL) 200 mg (Days 7-11). FIL 200 mg + ATV 40 mg (Day 12 ); FIL 200 mg (Day 13); FIL + PRA 40 mg + ROS 10 mg (Day 14); FIL 200 mg (Days 15-17) in Treatment B Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence BA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FIL 200 mg (Days 1-5); FIL 200 mg + ATV 40 mg (Day 6); FIL 200 mg (Day 7); FIL + PRA 40 mg + ROS 10 mg (Day 8); FIL 200 mg (Days 9-11); Washout period (Days 12-17) in Treatment B Period 1. ATV 40 mg (Day 18); Washout period (Day 19); PRA 40 mg + ROS 10 mg (Day 20) in Treatment A Period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Administered as single dose tablet orally.</description>
    <arm_group_label>Sequence AB</arm_group_label>
    <arm_group_label>Sequence BA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin</intervention_name>
    <description>Administered as single dose tablet orally.</description>
    <arm_group_label>Sequence AB</arm_group_label>
    <arm_group_label>Sequence BA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Administered as single dose tablet orally.</description>
    <arm_group_label>Sequence AB</arm_group_label>
    <arm_group_label>Sequence BA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgotinib</intervention_name>
    <description>Administered as tablet orally once daily for 11 days.</description>
    <arm_group_label>Sequence AB</arm_group_label>
    <arm_group_label>Sequence BA</arm_group_label>
    <other_name>GS-6034</other_name>
    <other_name>GLPG0634</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Have the ability to understand and sign a written informed consent form (ICF), which&#xD;
             must be obtained prior to initiation of study procedures.&#xD;
&#xD;
          -  Be a nonsmoker. The use of nicotine or nicotine-containing products must be&#xD;
             discontinued 90 days prior to the first dose of study drug.&#xD;
&#xD;
          -  Have a calculated body mass index (BMI) of greater than or equal to (≥) 19.0 and less&#xD;
             than or equal to (≤) 30.0 kilogram per meter square (kg/m^2) at screening.&#xD;
&#xD;
          -  Have a creatinine clearance (CLcr) ≥ 90 milliliter per minute (mL/min) (using the&#xD;
             Cockcroft-Gault method) based on serum creatinine and actual body weight as measured&#xD;
             at screening and upon admission.&#xD;
&#xD;
          -  Female individuals of childbearing potential must have a negative serum pregnancy test&#xD;
             at screening and a negative urine pregnancy test at clinic admission.&#xD;
&#xD;
          -  Male individuals must be surgically sterile.&#xD;
&#xD;
          -  Male individuals and female individuals of childbearing potential who engage in&#xD;
             heterosexual intercourse must agree to use protocol-specified method(s) of&#xD;
             contraception.&#xD;
&#xD;
          -  Screening laboratory evaluations and 12-lead electrocardiogram (ECG) evaluations must&#xD;
             be without clinically significant abnormalities as assessed by the investigator.&#xD;
&#xD;
          -  Have liver biometric tests such as alanine aminotransferase (ALT), aspartate&#xD;
             aminotransferase (AST), alkaline phosphatase, and total bilirubin below the upper&#xD;
             limit of normal at screening.&#xD;
&#xD;
          -  Must be willing and able to comply with all study requirements.&#xD;
&#xD;
          -  Must, in the opinion of the investigator, be in good health based upon medical history&#xD;
             and physical examination, including vital signs.&#xD;
&#xD;
          -  Individuals must not have donated blood within 56 days of study entry or plasma within&#xD;
             7 days of study entry and must refrain from blood donation from clinic admission,&#xD;
             throughout the study period, and continuing for at least 30 days following the last&#xD;
             dose of study drug.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Positive serum pregnancy test (Female individuals).&#xD;
&#xD;
          -  Lactating female.&#xD;
&#xD;
          -  Have received any investigational drug/device within 30 days prior to study dosing (or&#xD;
             within 5 half-lives of the drug, whichever is longer).&#xD;
&#xD;
          -  Have current alcohol or substance abuse judged by the investigator to potentially&#xD;
             interfere with participant compliance or participant safety, or a positive drug or&#xD;
             alcohol test at screening or admission.&#xD;
&#xD;
          -  Have a positive test result for human immunodeficiency virus type 1 (HIV-1) antibody,&#xD;
             hepatitis B virus (HBV) surface antigen (HBsAg), or hepatitis C virus (HCV) antibody&#xD;
             at screening.&#xD;
&#xD;
          -  Have positive Coronavirus Disease 2019 (COVID-19) Real-Time Reverse.&#xD;
&#xD;
          -  Transcriptase-Polymerase Chain Reaction (RT-PCR) testing on screening and admission.&#xD;
&#xD;
          -  Have poor venous access that limits phlebotomy.&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prism Research, LLC</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 23, 2020</study_first_submitted>
  <study_first_submitted_qc>October 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2020</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

